

1 **Association between Renal Function and Retinal Neurodegeneration in Chinese**
2 **Patients with Type 2 Diabetes Mellitus**

3 **Running title: Renal Function and Retinal Neurodegeneration**

4 Xia GONG, MD¹, Wei WANG, MD, PhD¹, Wangting LI, MD¹, Ling JIN, MS¹, Lanhua
5 WANG, MD¹, Jie MENG, MD¹, Kun XIONG, MD¹, Yuting LI, MPH¹, Xiao HAN,
6 MD², Xiaoling LIANG, MD, PhD¹, Yizhi LIU, MD, PhD¹, Wenyong HUANG, MD,
7 PhD¹

8

9 1. Zhongshan Ophthalmic Center, State Key Laboratory of Ophthalmology, Sun
10 Yat-Sen University, Guangzhou, People's Republic of China

11 2. The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, People's
12 Republic of China

13

14 **Corresponding author:**

15 Wenyong Huang, MD&PhD

16 Professor of Ophthalmology, Zhongshan Ophthalmic Center, State Key Laboratory of
17 Ophthalmology, Sun Yat-sen University

18 54S.Xianlie Road, Guangzhou, China 510060

19 Email: hweny@mail.sysu.edu.cn; huangwenyong@gzzoc.com

20 Tel: +86-20-87333106, Fax:+86-20-87333106

21

22 **Word count for the main text:** 4300

23 **Table:** 4

24 **Figure:** 0

25

26 **Acknowledgements and Funding:** This work was supported by the National Natural
27 Science Foundation of China (grand numbers 81570843; 81530028; 81721003), the
28 Guangdong Province Science & Technology Plan (grant number 2014B020228002).

29 **Financial Conflict:** None

30 **Association between Renal Function and Retinal Neurodegeneration in Chinese**
31 **Patients with Type 2 Diabetes Mellitus**

32

33 **Abstract**

34 **Background:** Chronic kidney disease (CKD) and diabetic retinopathy (DR) are two
35 serious complications of diabetes. However, the association between retinal
36 neurodegeneration in DR and renal function decline is still unclear. Our objective was
37 to evaluate the association by measure estimated glomerular filtration rate (eGFR),
38 macular ganglion cell–inner plexiform layer (GC–IPL) and ganglion cell complex
39 (GCC) thickness in patients with type 2 diabetes mellitus (T2DM).

40

41 **Methods:** We analyzed the baseline data of the Guangzhou Diabetic Eye Study.
42 T2DM patients from communities in Guangzhou were enrolled and all participants
43 went through ophthalmic and general examinations. The thickness of the macular
44 GC–IPL and GCC in their right eyes were measured by swept-source optical coherence
45 tomography. CKD was defined as $eGFR < 60 \text{ mL/min/1.73 m}^2$.

46

47 **Results:** 1,309 patients were included (mean age 64.4 ± 7.6 years, 59.1% female), and
48 fifty-eight (4.4%) of them had CKD. Average macular GC–IPL thickness was
49 significantly thinner in CKD patients ($96.5 \pm 9.1 \mu\text{m}$) than non-CKD patients ($101.3 \pm$
50 $9.2 \mu\text{m}$) ($p < 0.01$). Average macular GCC thickness was also significantly thinner in

51 CKD patients ($123.5 \pm 13.2 \mu\text{m}$) than non-CKD patients ($129.9 \pm 12.8 \mu\text{m}$) ($p < 0.01$).

52 The significant thinning of macular GC-IPL and GCC thickness presented in every
53 grid in macula (all, $p < 0.05$) except for central grid ($p \geq 0.05$). In the patients without
54 DR, the eGFR was linearly correlated with the average macular GC-IPL thickness ($\beta =$
55 0.07 [95% CI $0.02\text{--}0.12$], $p < 0.01$) and GCC thickness ($\beta = 0.09$ [95% CI $0.03\text{--}0.16$],
56 $p < 0.01$) after adjustment for age, sex, axial length, intraocular pressure and
57 combination of hypertension. However, no linear correlation was found between eGFR
58 and macular GC-IPL or GCC thickness in DR patients.

59

60 **Conclusions:** Renal function decreases is associated with the thinning of the macular
61 GC-IPL and GCC in T2DM patients, suggesting the potential value of ganglion cell
62 lose to detect early function decline in the kidney in diabetic patients, especially in
63 patients without DR.

64

65 **Key Words:** diabetes, neurodegeneration, optical coherent tomography, renal function

66

67 **1. Background**

68 Chronic kidney disease (CKD) is one of the major complications in diabetic
69 patients. CKD is not only a cause of renal failure, but also an independent risk factor
70 for cardiovascular disease, cognitive dysfunction, and all-cause mortality. With the
71 increasing diabetic patients, the number of patients with CKD has increased
72 dramatically in recent decades and has become one of the greatest global health
73 challenges of our time.^{1,2} However, most CKD patients were diagnosed after renal
74 function obvious decline. Thus it is important to detect renal impairment in the early
75 stage of CKD development.²

76 Diabetic retinopathy (DR) is another major complications in diabetic patients.³ In
77 many countries, DR, which develops in approximately 20–40% of diabetic patients,⁴ is
78 the most common cause of avoidable blindness in the working-age population.⁵
79 Diabetic patients are suggested to take regular screening for DR.

80 Because both CKD and DR are microvascular complications of diabetes,
81 researchers suggested that CKD and DR may be closely linked.⁶ The earliest clinical
82 feature of DR is vascular changes, while retinal ganglion cell–inner plexiform layer
83 (GC–IPL) thickness and ganglion cell complex (GCC) thickness are known to be early
84 indicators of hyperglycemia-induced neurodegeneration prior to the detectability of
85 clinical microvascular abnormalities.⁷⁻⁹ Hyperglycemia-induced neurodegeneration
86 affects primarily the retinal ganglion cell nuclei and dendrites. This then affects the
87 axons of the ganglion cell, and this is manifested as the diffuse thinning of the retinal

88 GC-IPL followed by the thinning of the retinal nerve fiber layer (RNFL).⁷ Since GCC
89 is the combination of GC-IPL and RNFL, it will become thinner in this process.
90 Moreover, researchers suggested that neurodegeneration in retina may associated with
91 renal function decline in diabetic patients.¹⁰

92 However, the association of the important parameters of neurodegeneration in DR
93 development, including the thickness of the macular GC-IPL and GCC, with the eGFR
94 (the most valuable indicator of overall renal function),¹¹ has not been elucidated. To fill
95 this gap, we analyzed the baseline data of the Guangzhou Diabetic Eye Study to
96 evaluate the associations. This study is the first to use swept-source optical coherence
97 tomography (SS-OCT) to investigate the association between retinal ganglion cell loss
98 and renal function in T2DM patients in China.

99 We present the following article/case in accordance with the Strengthening the
100 Reporting of Observational Studies in Epidemiology (STROBE) reporting checklist.

101

102 **2. Methods**

103 **2.1. Subjects**

104 The Guangzhou Diabetic Eye Study is a prospective study conducted in the
105 Zhongshan Ophthalmic Center, which is affiliated with Sun Yat-Sen University in
106 Guangzhou, China. The study protocol was approved by the Zhongshan Ophthalmic
107 Center Ethics Committee. Written consent was obtained from all participants before

108 they entered the study. This article analyzed its baseline data collected from October
109 2018 to April 2019

110 The study recruited 1,473 T2DM patients between the ages of 30 and 80. They
111 were already registered in the health care systems in the communities near the
112 Zhongshan Ophthalmic Center. Patients with any evidence of the following conditions
113 were excluded: (1) best corrected visual acuity (BCVA) worse than 20/200, axial
114 length > 30 mm or unmeasurable, spherical equivalent (SphE) ≤ -12.0 degrees,
115 astigmatism > 4 degrees, or intraocular pressure > 21 mmHg in the study eye; (2)
116 except DR, other combined eye diseases that could affect retinal thickness in the study
117 eye, such as glaucoma, age-related macular degeneration, and retinal detachment; (3)
118 surgery or invasive treatment or laser treatment history on the study eye; (4) severe
119 systemic diseases, such as uncontrolled hypertension, severe cardiovascular and
120 cerebrovascular disease, malignant tumors, and nephritis; (5) general surgery history,
121 such as heart bypass, thrombolysis, and kidney transplantation; (6) cognitive disorders
122 or mental illness that would hinder the patient's cooperation with tests; and (7)
123 inability to obtain clear fundus or SS-OCT images because of refractive media opacity
124 or noncooperation.

125 We excluded 40, 47, 77 patients for unqualified general condition, eye condition
126 or image quality, respectively.

127

128 **2.2. General Information and Laboratory Measurements**

129 Upon enrollment in the study, general information, including age, sex, diabetes
130 duration, other combined systemic chronic diseases, medication compliance, and
131 smoking and drinking histories, were collected via questionnaires.

132 Height and weight were manually measured. Body mass index (BMI) was defined
133 as weight (kg) divided by the square of height (m), and a patient with a BMI of
134 23–27.5 kg/m² or >27.5 kg/m² was considered to be overweight or obese,
135 respectively.¹²

136 Each patient's systolic blood pressure (SBP) and diastolic blood pressure (DBP)
137 were measured by electronic sphygmomanometer (Hem-907, Omron, Kyoto, Japan).
138 The mean artery pressure (MAP) was calculated to be the sum of 1/3 SBP and 2/3
139 DBP.

140 Blood and urine samples were collected by experienced nurses. Serum creatinine,
141 hemoglobin A1c (HbA1c), total cholesterol (TC), high-density lipoprotein cholesterol
142 (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), C-reactive
143 protein, and microalbuminuria were measured. The eGFR was calculated with the
144 Xiangya formula, which has been reported to be the most accurate eGFR formula for
145 the Chinese population.¹³ CKD was defined as an eGFR lower than 60/min/1.73 m².¹⁴

146 Participants who had abnormal observations or intake of related drugs were
147 defined as hypertension or hyperlipidemia.

148

149 **2.3. Eye Examination**

150 Each participant underwent a comprehensive ocular examination that included the
151 best correct visual acuity (BCVA) test (Early Treatment Diabetic Retinopathy Study
152 [ETDRS] LogMAR visual acuity chart, Precision Vision, Artesia, USA), refraction
153 powers examination (auto refractometer, KR-8800, Topcon, Tokyo, Japan), intraocular
154 pressure (IOP) measurement (non-contact tonometer, CT-1, Topcon, Tokyo, Japan), slit
155 lamp examination, and ocular biometric measurements (Lenstar LS900, Haag-Streit,
156 Koeniz, Switzerland). The SphE was calculated as the sphere degree plus 1/2 cylinder
157 degree. The standard ETDRS 7-field fundus photography (CR-2, Canon, Tokyo, Japan)
158 was obtained after the pupil was dilated with 3 drops of tropicamide phenylephrine
159 (Mydorin, Santen, Osaka, Japan). The images were graded by two well-trained graders
160 in accordance with the English National Health Service Diabetic Eye Screening
161 Programme Grading Classification Standard.¹⁵

162

163 **2.4. Swept-Source Optical Coherence Tomography**

164 A SS-OCT device (DRI OCT Triton, Topcon, Tokyo, Japan) was used to scan the
165 fovea area. A three-dimensional (3D) imaging scan protocol of native software
166 (10.15.003.01) was used to evaluate a 6 × 6 mm region of the macula. The scans were
167 centered automatically and confirmed by a fundus camera that was integrated into the

168 instrument. In accordance with the ETDRS standard, three circles with diameters of 1,
169 3, 6mm divided the fovea into a central grid, an inner ring and an outer ring; then inner
170 ring and outer ring were divided into four quadrants, including superior, inferior, nasal
171 and temporal quadrants. The thickness profiles of the GC-IPL and GCC layers were
172 automatically produced, and thickness of GC-IPL or GCC in each grid was
173 automatically reported.

174 The examinations were performed by an experienced examiner with no
175 knowledge of the study protocol. Each participant's measurements were obtained
176 through dilated pupil. The exclusion of unqualified images, including out-of-focus
177 images or those with motion artifacts or segmentation algorithm failures, was
178 performed at a different time from that of image acquisition.

179

180 **2.5. Statistical Analysis**

181 The data from each participant's right eye was analyzed. The difference in
182 characteristics between the CKD patients and non-CKD patients was evaluated through
183 the independent samples *t*-test for the normally distributed data, Spearman's rank-sum
184 test for the non-normally distributed data, and chi-square test for the qualitative data
185 respectively. Univariate and multivariate linear regressions were used to evaluate the
186 relationships between the eGFR and macular GC-IPL and GCC thickness. Model 1 of
187 the multivariable linear regression was adjusted for the factors known to be relevant to

188 macular GC–IPL and GCC thickness. These factors included age, sex, and axial
189 length.¹⁶ Model 2 was further adjusted for the parameters that were associated with
190 macular GC–IPL and GCC thickness in the univariable linear regression. These factors
191 included hypertension and IOP. A *p*-value of <0.05 was considered significant.

192

193 **3. Results**

194 A total of 1,309 diabetic patients (59.1% female) were included in the final
195 analysis. The demographic and clinical characteristics are presented in Table 1. They
196 had an average age of 64.4 ± 7.6 years (mean \pm standard deviation [*SD*]). The median
197 (interquartile range) diabetic duration was 7.0 (3.0–13.0) years. The proportion of
198 overweight (51.6%), obesity (16.8%), hypertension (56.5%), or hyperlipidemia (47.2%)
199 were high. Participants had a vision of average LogMAR BCVA (*SD*) 0.2 (0.1).
200 Among the participants, 1,094 (83.6%) had no signs of DR and 215 (16.4%) had DR.

201 Fifty-eight (4.4%) participants had CKD. CKD patients were older than non-CKD
202 patients (70.7 ± 6.6 years for CKD, 64.1 ± 7.5 years for non-CKD, *p* < 0.01). In
203 addition, CKD patients had longer diabetes duration, higher BMI, higher C-reactive
204 protein, higher microalbuminuria, worse BCVA, and, unexpectedly, lower IOP. The
205 CKD patients were more likely to have hypertension, hyperlipidemia and have a
206 requirement for insulin treatment (all *p* < 0.05).

207 Table 2 shows the macular GC–IPL and GCC thickness in CKD patients and
208 non-CKD patients. The average macular GC–IPL was thinner in CKD patients than
209 non-CKD patients, with measurements of $101.3 \pm 9.2 \mu\text{m}$ for non-CKD, $96.5 \pm 9.1 \mu\text{m}$
210 for CKD, respectively ($p < 0.01$). The average macular GCC was also thinner in CKD
211 patient than non CKD patients, with measurements of $129.9 \pm 12.8 \mu\text{m}$ for non-CKD,
212 $123.5 \pm 13.2 \mu\text{m}$ for CKD, respectively ($p < 0.01$). The macular GC–IPL and GCC in
213 the CKD patients were significantly thinner than non-CKD patients in almost every
214 grid (all, $p < 0.05$), except for central grid ($p \geq 0.05$).

215 Table 3 presents the results of the univariate linear regression analysis between
216 participants' characteristics and thickness of macular GC-IPL and GCC. Not only the
217 eGFR but also age, sex, axial length, IOP, and combination of hypertension or DR
218 were significantly linearly correlated with macular GC–IPL and GCC thickness (all, p
219 < 0.05).

220 Table 4 shows the results of the multivariate linear regression. To reduce the effect
221 of the presence of DR, participants with and without DR were analyzed separately.
222 Model 1 was adjusted for the factors known to be relevant to macular GC–IPL and
223 GCC thickness. These included age, sex, and axial length. Model 2 further adjusted for
224 the parameters associated with macular GC–IPL and GCC thickness in the univariate
225 model. In the patients without DR, the linear correlation between the eGFR and
226 GC–IPL and GCC persisted in all the models (all, $p < 0.01$). In model 2, eGFR was
227 linearly correlated with the macular GC–IPL ($\beta = 0.07$ [95% CI 0.02–0.012], $p < 0.01$)

228 and GCC thickness ($\beta = 0.09$ [95% CI 0.03–0.016], $p < 0.01$). However, in the DR
229 patients, there was no significant linear correlation between eGFR and macular
230 GC-IPL or GCC thickness (all, $p \geq 0.05$).

231

232 **4. Conclusions**

233 We have two main results: (1) The average macular GC–IPL and GCC thickness
234 decreased in the CKD patients. (2) The eGFR was positively correlated with the
235 average macular GC–IPL and GCC thickness independent of age, sex, axial length, and
236 other potential confounding factors in patients without DR. Our results show a close
237 association between retinal neurodegeneration and renal dysfunction and suggests that
238 neurodegeneration progressed as renal function deteriorated. Thus, the potential for
239 macular GC–IPL and GCC thickness to be indicative of early hyperglycemia-induced
240 impairment in the eye and kidney in T2DM patients was supported.

241 We also have a few negative results. First, the macular GC–IPL and GCC thinning
242 in CKD patients was found in every grid except the central grid. This could have been
243 caused by the lower density of the ganglion cells in the fovea pit.¹⁷ Second, no
244 significant linear correlation was found between macular GC–IPL and GCC thickness
245 and the eGFR in the DR patients. One possible reason is the relatively small sample
246 size (215) of DR patients. Another is that the increase in retinal thickness in DR
247 patients might have obscured the GC–IPL and GCC thinning caused by the loss of

248 ganglion cells. In the progression of DR, retinal capillary leakage would lead to retinal
249 edema.¹⁸ Moreover, it has been hypothesized that ganglion cell degeneration could
250 play a role in the blood-retinal barrier breakdown which could induce retinal edema in
251 the development of DR.¹⁹ The results of the linear regressions indicate that the macular
252 GC–IPL and GCC in the DR patients tended to be thicker than patients without DR.
253 Before diabetic macular edema becomes clinically significant, morphologic changes
254 might not be observable in OCT images. It is assumed that the evaluation of
255 neurodegeneration through OCT might be more valuable for patients without DR.

256 The retinal and renal glomerular microvasculature have many similarities, and
257 diseases of these organs have a common pathogenesis. However, few studies have
258 evaluated the association between neurodegeneration and renal function in diabetic
259 patients. Srivastav et al. reported that an increase in serum creatinine levels was
260 associated with RNFL thinning in diabetic patients.¹⁰ However, the study included only
261 60 diabetic patients and considered few relative factors. Moreover, serum creatinine
262 has limited value as a single indicator of renal function because more than half of the
263 patients with an eGFR of <60 ml/min/1.73 m² might have normal serum creatinine
264 levels.¹⁴ The present study enrolled a large sample of T2DM patients in local
265 communities and adjusted for multiple potential confounding factors. Thus, renal
266 function was confirmed to be independently correlated with retinal neurodegeneration
267 in diabetic patients.

268 There are also limitations. First, as was previously mentioned, the use of macular
269 GC-IPL and GCC thickness to evaluate ganglion cell loss might have been
270 confounded by the presence DR. Because of the uneven distribution of DR patients,
271 further studies are necessary to investigate retinal neurodegeneration and its
272 association with renal function in patients with various severity levels of DR. Second,
273 we only analyzed the baseline data; thus, it is also necessary to further investigate the
274 synchronization of retinal neurodegeneration and renal function decline. Follow-up
275 visits are ongoing. Third, this was not a population-based or hospital-based study. The
276 participants were recruited from communities voluntarily. A majority did not have DR
277 or CKD; thus, the generalization of the findings to other diabetic patients should be
278 considered with caution. Most patients with diabetes in China are located in
279 communities, thereby this study still can represent a large population.

280 In summary, we found that retinal neurodegeneration progress with deterioration
281 of renal function in Chinese T2DM patients. OCT is a non-invasive tool which can
282 quantitatively evaluate GC-IPL and GCC thicknesses, but the evaluation is more
283 valuable for patients without DR.

284

285 **Author contribution**

286 W Huang and W Wang conceived and designed the study. X Gong, W Li, W Wei, L
287 Wang, J Meng, Y Li, K Xiong and X Han collected and interpreted the data. X Gong
288 and L Jin carried out the statistical analysis. X Gong wrote the manuscript. W Huang,
289 W Wang, and W Li reviewed and edited the manuscript. All authors have seen the final
290 version of the manuscript and approved it for publication.

291 **Acknowledgements and Funding:** This work was supported by the National Natural
292 Science Foundation of China (grant numbers 81570843; 81530028; 81721003), the
293 Guangdong Province Science & Technology Plan (grant number 2014B020228002).

294 **Financial Disclosure:** No potential conflicts of interest relevant to this article were
295 reported.

296

297 **References**

- 298 1. Drawz P RM. Chronic Kidney Disease. *Ann Intern Med.* 2015;162:C1-16.
- 299 2. Anders HJ HTIB. CKD in Diabetes: Diabetic Kidney Disease Versus Nondiabetic
300 Kidney Disease. *Nat Rev Nephrol.* 2018;14:361-77.
- 301 3. Zheng Y, Ley SH, Hu FB. Global Aetiology and Epidemiology of Type 2 Diabetes
302 Mellitus and Its Complications. *Nat Rev Endocrinol.* 2018;14:88-98.
- 303 4. Saaddine JB, Honeycutt AA, Narayan KMV, et al. Projection of Diabetic
304 Retinopathy and Other Major Eye Diseases Among People With Diabetes Mellitus:
305 United States, 2005-2050. *Archives of Ophthalmology* 2008;126:1740-7.
- 306 5. Mohamed Q GMWT. Management of Diabetic Retinopathy: A Systematic Review.
307 *JAMA.* 2007;298:902-16.
- 308 6. Barber AJ. Diabetic Retinopathy: Recent Advances towards Understanding
309 Neurodegeneration and Vision Loss. *Science China Life Sciences* 2015;58:541-9.
- 310 7. Carpineto P TLAR. Neuroretinal Alterations in the Early Stages of Diabetic
311 Retinopathy in Patients with Type 2 Diabetes Mellitus. *Eye.* 2016;30:673-9.
- 312 8. Pierro L, Iuliano L, Cicinelli MV, et al. Retinal Neurovascular Changes Appear
313 Earlier in Type 2 Diabetic Patients. *Eur J Ophthalmol.* 2017;27:346-51.

- 314 9. Wong CW, Wong TY, Cheng C, Sabanayagam C. Kidney and Eye Diseases:
315 Common Risk Factors, Etiological Mechanisms, and Pathways. *Kidney Int.*
316 2014;85:1290-302.
- 317 10. Srivastav K, Saxena S, Mahdi AA, et al. Increased Serum Urea and Creatinine
318 Levels Correlate with Decreased Retinal Nerve Fibre Layer Thickness in Diabetic
319 Retinopathy. *Biomarkers* 2015;20:470-3.
- 320 11. Li DY YWYY. What Is the Best Glomerular Filtration Marker to Identify People
321 with Chronic Kidney Disease Most Likely to Have Poor Outcomes. *Kidney Int.*
322 2019;95:636-46.
- 323 12. Consultation WE. Appropriate Body-mass Index for Asian Populations and Its
324 Implications for Policy and Intervention Strategies. *The Lancet* 2004;9403:157-63.
- 325 13. Li D, Yin W, Yi Y, et al. Development and Validation of a More Accurate
326 Estimating Equation for Glomerular Filtration Rate in a Chinese population. *Kidney Int.*
327 2019;95:636-46.
- 328 14. Thomas MC BMSK. Diabetic Kidney Disease. *Nat Rev Dis Primers.* 2015;1.
- 329 15. Harding S, Greenwood R, Aldington S, et al. Grading and disease management in
330 national screening for diabetic retinopathy in England and Wales. *Diabet Med.*
331 2003;20:965-71.

- 332 16. Knight ORJ, Girkin CA, Budenz DL, et al. Effect of Race, Age, and Axial Length
333 on Optic Nerve Head Parameters and Retinal Nerve Fiber Layer Thickness Measured
334 by Cirrus HD-OCT. *Archives of Ophthalmology* 2012;130:312-8.
- 335 17. Chui TY SHBS. Adaptive-optics Imaging of Human Cone Photoreceptor
336 Distribution. *J Opt Soc Am A Opt Image Sci Vis.* 2008;25:3021-9.
- 337 18. Cheung N MPWT. Diabetic Retinopathy. *Lancet.* 2010;9735:124-36.
- 338 19. FDAJ CJ. Early Breakdown of the Blood-retinal Barrier in Diabetes. *Br J*
339 *Ophthalmol.* 1975;59:649-56.

Table 1 Participant's Characteristics Stratified by the Presence of Chronic Kidney Diseases.

| Characteristics | All participants | CKD | Non-CKD | P-value |
|---|------------------|-----------------|----------------|-------------------------------|
| No. (eyes) | 1309 | 58 | 1251 | |
| Age, mean (SD), year | 64.4 (7.6) | 70.7 (6.6) | 64.1 (7.5) | <0.001 [†] |
| Sex | | | | 0.684 [§] |
| Male, % | 40.9 | 37.9 | 41.0 | |
| Female, % | 59.1 | 62.1 | 59.0 | |
| Body mass index, mean (SD), kg/m ² | 24.6 (3.2) | 25.6 (3.3) | 24.5 (3.2) | 0.018 [†] |
| Diabetes: | | | | |
| Duration of diabetes, median (IQR), year | 7.0 (3.0-13.0) | 11.0 (5.0-17.0) | 7.0 (3.0-13.0) | 0.002 [‡] |
| HbA1c, mean (SD), % | 7.0 (1.5) | 6.9 (1.5) | 7.0 (1.5) | 0.847 [†] |
| Use of insulin treatment, % | 20.9 | 36.2 | 20.1 | 0.019 [§] |
| Diabetic retinopathy, % | 16.4 | 23.2 | 16.4 | 0.199 [§] |
| Blood pressure: | | | | |
| Hypertension, % | 56.5 | 91.4 | 54.9 | <0.001 [§] |
| SBP, mean (SD), mmHg | 134.6 (19.0) | 138.4 (19.2) | 134.4 (19.0) | 0.123 [†] |
| DBP, mean (SD), mmHg | 70.0 (11.8) | 70.8 (9.3) | 69.6(11.9) | 0.460 [†] |
| MAP, mean (SD), mmHg | 92.0 (11.9) | 93.3 (11.4) | 92.0 (11.9) | 0.405 [†] |
| Blood lipid: | | | | |
| Hyperlipidemia, %: | 47.2 | 69.0 | 46.2 | 0.001 [§] |
| TG, mean (SD), mmol/L | 2.3 (1.6) | 2.6 (2.0) | 2.3 (1.6) | 0.121 [†] |
| LDL-C, mean (SD), mmol/L | 3.1 (0.9) | 3.2 (1.1) | 3.1 (0.9) | 0.523 [†] |
| HDL-C, mean (SD), mmol/L | 1.3 (0.4) | 1.2 (0.4) | 1.3 (0.4) | 0.107 [†] |
| TC, mean (SD), mmol/L | 4.8 (1.0) | 5.0 (1.2) | 4.8 (1.0) | 0.266 [†] |

| | | | | |
|---|----------------|----------------|----------------|------------------------------|
| C-reactive protein, median (IQR), mg/dL | 1.4 (0.7- 2.7) | 2.0 (1.0- 3.8) | 1.4 (0.7- 2.6) | 0.027[‡] |
| Renal function: | | | | |
| eGFR, mean (SD), mL/min/1.73 m ² | 76.2 (10.7) | 54.2 (5.2) | 77.2 (9.8) | <0.001[†] |
| Serum creatinine, mean (SD), μmol/L | 71.4 (21.6) | 123.8 (35.5) | 69.0 (17.3) | <0.001[†] |
| Microalbuminuria, median (IQR), mg/L | 0.9 (0.3-2.8) | 5.4 (1.4-21.0) | 0.9 (0.3- 2.7) | <0.001[‡] |
| Eye examination: | | | | |
| LogMAR BCVA, mean (SD) | 0.2 (0.1) | 0.3 (0.1) | 0.2 (0.1) | 0.001[†] |
| IOP, mean (SD), mmHg | 15.9 (2.5) | 15.0 (2.7) | 15.9 (2.4) | 0.011[†] |
| Axial length, mean (SD), mm | 23.5 (1.1) | 23.5 (1.1) | 23.5 (1.1) | 0.817 [†] |
| SphE, mean (SD), degree | 0.2 (2.2) | 0.2 (2.0) | 0.2(2.2) | 0.903 [†] |

Abbreviations: CKD, chronic kidney diseases; SD, standard deviation; IQR, interquartile range; SBP, systolic blood pressure; DBP, diastolic pressure; MAP, mean artery pressure; TG, triglyceride; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; TC, total cholesterol; eGFR, estimated glomerular filtration rate; BCVA, best corrected visual acuity; IOP, intraocular pressure; SphE, spherical equivalent.

CKD defined as eGFR<60 mL/ min/1.73 m².

[†] Independent two-sample *t* test

[‡] Spearman's rank-sum test

[§] Chi-square test

Table 2 Thickness of Macular Ganglion Cell-inner Plexiform Layer and Ganglion Cell Complex Stratified by the Presence of Chronic Kidney Diseases.

| Parameters | CKD (μm) | Non-CKD (μm) | P-value [†] |
|--------------------------|-----------------------|---------------------------|----------------------|
| Macular GC-IPL thickness | 96.5 (9.1) | 101.3 (9.2) | <0.001 |
| Central grid | 43.2 (14.0) | 45.5 (18.0) | 0.339 |
| Inner nasal grid | 103.6 (13.2) | 109.8 (13.2) | 0.001 |
| Inner superior grid | 112.4 (11.7) | 116.5 (12.2) | 0.011 |
| Inner temporal grid | 100.9 (10.9) | 104.7 (11.5) | 0.012 |
| Inner inferior grid | 108.0 (14.6) | 114.0 (13.4) | 0.003 |
| Average inner ring | 106.2 (10.4) | 111.3 (10.9) | 0.001 |
| Outer nasal grid | 113.3 (14.8) | 119.0 (11.4) | 0.006 |
| Outer superior grid | 101.2 (12.5) | 106.0 (12.2) | 0.006 |
| Outer temporal grid | 88.3 (8.5) | 92.3 (10.4) | 0.001 |
| Outer inferior grid | 97.1 (13.6) | 103.5 (11.1) | 0.001 |
| Average outer ring | 100.0 (10.6) | 105.2 (9.8) | 0.001 |
| Macular GCC thickness | 123.5 (13.2) | 129.9 (12.8) | 0.001 |
| Central grid | 47.3 (18.6) | 49.8 (22.5) | 0.414 |
| Inner nasal grid | 125.8 (17.4) | 133.2 (17.0) | 0.002 |
| Inner superior grid | 139.6 (15.2) | 145.0 (16.6) | 0.012 |
| Inner temporal grid | 120.5 (14.1) | 124.9 (14.9) | 0.025 |
| Inner inferior grid | 133.5 (19.8) | 141.2 (17.9) | 0.005 |
| Average inner ring | 129.8 (13.6) | 136.1 (14.0) | 0.001 |
| Outer nasal grid | 158.4 (24.5) | 166.6 (18.0) | 0.014 |
| Outer superior grid | 141.0 (19.7) | 147.5 (18.9) | 0.018 |
| Outer temporal grid | 110.2 (11.6) | 115.5 (14.0) | 0.001 |
| Outer inferior grid | 135.3 (22.5) | 145.0 (20.8) | 0.002 |
| Average outer ring | 136.2 (16.5) | 143.7 (14.9) | 0.001 |

Abbreviations: CKD, chronic kidney diseases; SD, standard deviation; GC-IPL, ganglion cell-inner plexiform layer; GCC, ganglion cell complex.

CKD defined as eGFR < 60 mL/min/1.73 m².

[†] Independent two-sample *t* test

Table 3 Univariate Linear Regression Analysis of the Relationship between Characteristics and Thickness of Macular Ganglion Cell-inner Plexiform Layer or Ganglion Cell Complex.

| Characteristics | Macular GC-IPL thickness | | Macular GCC thickness | |
|------------------------------------|--------------------------|------------------|-----------------------|------------------|
| | Coefficient (95%CI) | P-value | Coefficient (95%CI) | P-value |
| Age, year | -0.31 (-0.37, -0.24) | <0.001 | -0.39 (-0.48, -0.30) | <0.001 |
| Gender, male | 1.44 (0.42, 2.45) | 0.006 | 1.82 (0.39, 3.24) | 0.012 |
| Body mass index, kg/m ² | -0.02 (-0.17, 0.14) | 0.802 | 0.01 (-0.21, 0.22) | 0.952 |
| Duration of diabetes, year | -0.03 (-0.10, 0.05) | 0.464 | -0.03 (-0.13, 0.08) | 0.626 |
| HbA1c, % | 0.21 (-0.13, 0.56) | 0.221 | 0.32 (-0.16, 0.80) | 0.193 |
| Use of insulin treatment | 0.56 (-0.67, 1.79) | 0.374 | 0.93 (-0.80, 2.65) | 0.292 |
| Diabetic retinopathy | 2.80 (1.46, 4.15) | <0.001 | 4.09 (-2.20, 5.97) | <0.001 |
| Hypertension | -1.80 (-2.80, -0.80) | <0.001 | -2.15 (-3.57, -0.74) | 0.003 |
| SBP, mmHg | -0.02 (-0.05, -0.00) | 0.091 | -0.01 (-0.05, -0.02) | 0.467 |
| DBP, mmHg | -0.00 (-0.04, 0.05) | 0.872 | 0.02, (-0.04, 0.08) | 0.433 |
| MAP, mmHg | -0.01 (-0.05, 0.03) | 0.657 | -0.01 (-0.05, 0.07) | 0.709 |
| Hyperlipidemia | -0.58 (-1.58, 0.42) | 0.258 | -0.71 (-2.12, 0.70) | 0.322 |
| TG, mmol/L | -0.18 (-0.48, 0.13) | 0.265 | -0.15 (-0.59, 0.28) | 0.482 |
| LDL-C, mmol/L | -0.35 (-0.89, 0.19) | 0.204 | -0.43 (-1.188, 0.33) | 0.263 |
| HDL-C, mmol/L | -0.17 (-1.06, 1.40) | 0.785 | 0.06 (-1.67, 1.78) | 0.949 |
| TC, mmol/L | -0.33 (-0.81, 0.16) | 0.185 | -0.40 (-1.08, 0.28) | 0.249 |
| C-reactive protein, mg/dL | -0.06 (-0.13, -0.01) | 0.099 | -0.08 (-0.18, 0.02) | 0.121 |
| Microalbuminuria, mg/L | -0.01 (-0.03, 0.02) | 0.609 | -0.00 (-0.04, 0.04) | 0.964 |
| eGFR, mL/min/1.73 m ² | 0.13 (0.08, 0.17) | <0.001 | 0.15 (0.09, 0.22) | <0.001 |
| IOP, mmHg | 0.23 (0.02, 0.43) | 0.029 | 0.32 (0.03, 0.60) | 0.030 |
| Axial length, mm | 0.20 (-0.27, 0.67) | 0.393 | 1.09 (0.43, 1.74) | 0.001 |

Abbreviations: GC-IPL, ganglion cell-inner plexiform layer; GCC, ganglion cell complex; 95%CI, 95% confidential interval; SD, standard deviation; SBP, systolic blood pressure; DBP, diastolic pressure; MAP, mean artery pressure; TG, triglyceride; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; TC, total cholesterol; IQR, interquartile range; eGFR, estimated glomerular filtration rate; IOP, intraocular pressure.

Table 4 Multivariate Linear Regression Analysis of the Relationship between Estimated Glomerular Filtration Rate (eGFR) and Thickness of Macular Ganglion Cell-inner Plexiform Layer or Ganglion Cell Complex.

| Parameters | No DR (n=1094) | | DR (n=215) | |
|--------------------------|---------------------|------------------|---------------------|---------|
| | Coefficient (95%CI) | P-value | Coefficient (95%CI) | P-value |
| Macular GC-IPL thickness | 0.14 (0.09, 0.19) | <0.001 | 0.10 (-0.05, 0.26) | 0.184 |
| Model 1 [†] | 0.07 (0.02, 0.12) | 0.006 | 0.05 (-0.12, 0.23) | 0.551 |
| Model 2 [‡] | 0.07 (0.02, 0.12) | 0.009 | 0.02 (-0.16, 0.20) | 0.831 |
| Macular GCC thickness | 0.18 (0.11, 0.24) | <0.001 | 0.08 (-0.15, 0.31) | 0.489 |
| Model 1 [†] | 0.10 (0.03, 0.16) | 0.004 | 0.00 (0.25, 0.25) | 0.990 |
| Model 2 [‡] | 0.09 (0.03, 0.16) | 0.006 | -0.04 (-0.30, 0.22) | 0.777 |

Abbreviations: DR, diabetic retinopathy; 95%CI, 95% confidential interval; GC-IPL, ganglion cell-inner plexiform layer; GCC, ganglion cell complex.

[†]Adjusted for age, gender, axial length.

[‡]Further adjusted for hypertension (yes=1; no=0), intraocular pressure.